loading...| Preferred Name |
blinatumomab |
|
| Synonyms |
MT-103 |
|
| Definitions |
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000487684 |
|
| altLabel |
MT-103 bispecific T-cell engager MT103 Blincyto MEDI-538 anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103 |
|
| cui |
C3864946 C4276437 C3853840 C3853839 |
|
| DATE FIRST PUBLISHED |
2006-06-02 |
|
| Date last modified |
2008-11-21 |
|
| definition |
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C62528 |
|
| notation |
CDR0000487684 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
blinatumomab |
|
| tui |
T116 T129 T121 |